Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study will test two drugs, isatuximab and lenalidomide, on patients who have undergone a type of stem cell transplant called Autologous Stem Cell Transplant. Doctors will give these drugs to patients who still have small amounts of cancer cells in their body, called MRD-positive. The goal is to see if the drugs can help keep the cancer from coming back.
This study will test two drugs, isatuximab and lenalidomide, on patients who have undergone a type of stem cell transplant called Autologous Stem Cell Transplant. Doctors will give these drugs to patients who still have small amounts of cancer cells in their body, called MRD-positive. The goal is to see if the drugs can help keep the cancer from coming back.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)
This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: